运脾柔肝方对便秘型肠易激综合征大鼠5-HT、VIP及SP影响的实验研究
Effects of Experimental Studies Yunpi Rougan Fang on 5-HT, VIP and SP in Constipation-predominant Irritable Bowel Syndrome Rats
-
摘要: 目的 通过观察运脾柔肝方对便秘型肠易激综合征(C-IBS)模型大鼠血清、肠组织5-羟色胺(5-HT)、血管活性肠肽(VIP)、P物质(SP)的影响,探讨运脾柔肝方对C-IBS模型大鼠的可能作用机制。方法 将42只Wistar大鼠,随机选取6只作为正常组,剩余36只大鼠采用冰水灌胃法造模14 d,评价模型,随机选取造模成功的30只大鼠,采用随机数字法分为运脾柔肝方中药低、中、高剂量组、莫沙必利组、模型对照组,每组6只。运脾柔肝方低、中、高剂量组分别以12.2、24.4、48.8 g/(kg·d)的给药剂量灌胃,莫沙必利组以莫沙必利混悬液1.35 mg/(kg·d)灌胃,模型对照组及空白组给予等量蒸馏水灌胃。14 d后观察各组大鼠一般情况,并检测各组大鼠血清5-HT、VIP、SP水平和肠组织5-HT、VIP的含量。结果 与空白组相比,模型对照组血清、结肠组织免疫组显5-HT、VIP的表达水平较正常组显著升高(P<0.01),而血清SP的表达水平则明显降低(P<0.05),不同剂量运脾柔肝方均可显著降低C-IBS模型大鼠血清5-HT、VIP的表达水平(P<0.01),明显升高大鼠血清SP水平(P<0.05),免疫组化结果显示各组均能明显降低5-HT在肠组织中的表达(P<0.05),显著降低VIP的表达(P<0.01)。结论 运脾柔肝方可显著改善C-IBS模型大鼠便秘症状,可能是通过降低5-HT、VIP和升高SP的表达水平,从而调节肠道功能,发挥治疗C-IBS的作用。
-
关键词:
- 运脾柔肝方 /
- 便秘型肠易激综合征 /
- 5-羟色胺:血管活性肠肽 /
- P物质
Abstract: OBJECTIVE To observe the effects of Yunpi Rougan Fang on serum and colon tissue serum serotonin(5-HT), vasoactive peptide(VIP) and substance P(SP) in constipation-predominant irritable bowel syndrome rats, to explore its possible mechanism and relevance. METHODS 42 SPF Wistar rats, Six rats were randomly selected as normal group,the remaining 36 rats were modeled by ice water for 14 d,evaluation model, 30 rats were randomly selected and randomly divided into Chinese medicine high, medium and low dose group, western medicine group, model control group, each group had 6 rats. The Chinese medicine low, middle and high dose groups were treated with 12.2, 24.4, 48.8 g/(kg·d), Mosapride group with moxapril suspension 1.35 mg/(kg·d) gavage,model control group and blank group were given equal amount of distilled water to fill the stomach.After 14 d, the levels of 5-HT, VIP and SP in the serum and the levels of 5-HT and VIP in the colon tissue were measured. RESULTS Compared with the blank group, the expression of 5-HT and VIP in serum and colon tissue immunization in the model control group was increased significantly(P<0.01),the expression of SP in serum was decreased (P<0.05).Different doses can decrease the levels of serum 5-HT and VIP in C-IBS model rats (P<0.01), significantly increased the serum SP level (P<0.05). Immunohistochemical results showed that the expression of 5-HT in colon tissue was significantly decreased (P<0.05), and the expression of VIP was significantly decreased (P<0.01). Although the expression of each treatment group no significant difference (P>0.05), from the numerical changes, Yunpi Rougan Fang was superior to mosapride and showed dose-dependency. CONCLUSION Yunpi Rougan Fang can obviously improve the symptoms of constipation in C-IBS model rats, by reducing the expression of 5-HT and VIP, improving the expression of SP to regulate intestinal function, which plays a therapeutic role in C-IBS.-
Key words:
- Yunpi Rougan Fang /
- constipation-predominant irritable bowel syndrome /
- 5-HT /
- VIP
-
[1] FOXX-ORENSTEIN AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists[J]. Therp Adv Gastroenterol, 2016, 9(3): 354-375. [2] FUKUDO S, KANEKO H, AKIHO H, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome[J]. J Gastroenterol, 2015, 50(1): 11-30. [3] 李上云,吴耀南.中医药治疗便秘型肠易激综合征研究进展[J].中医药通报,2014, 13(6):64-66. [4] LI SY, WU YN. Research progress of traditional Chinese medicine in treating constipated irritable bowel syndrome[J]. Tradit Chin Med J, 2014, 13(6): 64-66. [5] 孙建梅,田耀洲.田耀洲教授治疗便秘型肠易激综合征[J].吉林中医药,2017, 37(2):122-124. [6] SUN JM, TIAN YZ. Professor TIAN Yaozhou in the treatment of constipation-predominant irritable bowel syndrome[J]. Jilin J Tradit Chin Med, 2017, 37(2): 122-124. [7] 彭丽华,杨云生,孙刚,等.便秘型肠易激综合征新概念模型的建立[J].世界华人消化杂志,2004, 12(1):112-116. [8] PENG LH, YANG YS, SUN G, et al. A new model of constipation-predominant irritable bowel syndrome in rats[J]. World Chin J Dig, 2004, 12(1): 112-116. [9] 徐淑云,卞如濂,陈修.药理实验方法[M].第3版.北京:人民卫生出版社,2002. [10] XU SY, BIAN RL, CHEN X. Pharmacological Testing Method[M]. 3rd edition. Beijing: People's Medical Publishing House,2002. [11] 王石红,郭喜军,王红霞.加味二至方对便秘型肠易激综合征大鼠5-HT的影响[J].河南中医,2010, 30(1):42-43. [12] WANG DH, GUO XJ, WANG HX. Effect of modified erzhi prescription on 5-hydroxytryptamine in rats with irritable bowel syndrome of constipation[J]. Henan Tradit Chin Med, 2010, 30(1): 42-43. [13] CENAC N, ALTIER C, MOTTA JP, et al. Potentiation of TRPV4 signalling by histamine and serotonin: an important mechanism for visceral hypersensitivity[J]. Gut, 2010, 59(4): 481-488. [14] THIJSSEN AY, MUJAGIC Z, JONKERS DM, et al. Alterations in serotonin metabolism in the irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2016, 43(2): 272-282. [15] GERSHON MD, TACK J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders[J]. Gastroenterology, 2007, 132 (1): 397-414. [16] LU ZZ, YIN XJ, TENG WJ, et al. Comparative effect of electroacupuncture and moxibustion on the expression of substance P and vasoactive intestinal peptide in patients with irritable bowel syndrome[J]. J Tradit Chin Med, 2015, 35(4): 402-410. [17] MARGOLIS KG, GERSHON MD. Neuropeptides and inflammatory bowel disease[J]. Curr Opin Gastroenterol, 2009, 25(6): 503-511.
点击查看大图
计量
- 文章访问数: 1444
- HTML全文浏览量: 18
- PDF下载量: 1237
- 被引次数: 0